Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The authors reported that electrochemotherapy and electroporation-based treatments, both with and without cytotoxic drugs, show promise as safer and more effective options for breast cancer treatment, including metastatic cases and palliative care, in vitro and in vivo.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This review examines the role of cell adhesion molecules in the pathogenesis of various inflammatory and neoplastic skin diseases, suggesting their potential utility in diagnosis and treatment without presenting new clinical results.

This study evaluated the effects of topical glucocorticoids on human skin using non-invasive imaging methods and observed changes such as alterations in skin layer thickness, keratinocyte size, and collagen and elastin signal intensity.

This review discusses the management of adverse events associated with sacituzumab govitecan use in real-world settings and provides no new clinical results; it emphasizes practical strategies for clinicians treating breast cancer patients.

This study found that reported stress and hair growth changes related to facial/body hair excess or scalp hair loss differ among ethnic gender minority groups, with black and other ethnic respondents experiencing more stress compared to Caucasians, particularly in relation to facial/body hair excess.

Early detection and skin biopsies are crucial for treating skin cancer and diagnosing various skin conditions.

This study found that methotrexate treatment for 15 days suppressed tuberculin hypersensitivity in Strain 2 guinea pigs without causing lymphopenic or anti-inflammatory effects.

This study found that nanobubble-encapsulated diclofenac with ultrasound-targeted microbubble destruction (DNBs-UTMD) can enhance the anti-tumor efficacy of Doxil® by regulating the tumor immune microenvironment, improving drug uptake, and increasing T cell responses while reducing immune-suppressive cells in the process.

This article discusses dutasteride, a new drug for managing benign prostatic hyperplasia, and highlights the need for further experience to confirm its safety and efficacy.

This review discusses the mechanism and side effects of smoothened inhibitors for advanced basal cell carcinoma, reporting no new clinical results and highlighting current management strategies for these adverse events.

This abstract outlines the current understanding of cutaneous squamous cell carcinoma (cSCC), identifying it as the second most common non-melanoma skin cancer with risk factors like UV exposure and immunosuppression. It highlights cSCC's potential to metastasize and become fatal, affecting 2%-5% of in situ cases.

In this study, two methotrexate-loaded liquid crystal formulations for topical application showed immunomodulatory effects and induced skin changes in mice with imiquimod-induced psoriasis.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

Docetaxel, a chemotherapy drug, was reported to cause psoriasis in a patient for the first time.

This study used in silico analysis to identify 4-[2-(4-nitrophenyl)ethylcarbamoyl]benzenesulfonyl as a potential inhibitor of the EGFR mutant associated with NSCLC, highlighting the need for further in vitro and in vivo validation.

In this study, researchers identified CENPV as a new CYLD interacting partner that localizes to primary cilia and regulates acetylated tubulin levels, offering insights into the pathogenesis of skin appendage tumors.

This review discusses current treatments for discoid lupus erythematosus and highlights anifrolumab as a promising option for difficult cases, but no new clinical results are reported.

This article discusses the effectiveness of adrenal cortex compounds E and F in treating connective tissue disorders like rheumatoid arthritis and lupus erythematosus, but it reports no new clinical results.

This study found that Chinese female patients with systemic autoimmune diseases treated intravenously with cyclophosphamide were more likely to experience gastrointestinal discomfort, myelosuppression, and alopecia.

This study suggests that the CsA-induced inactivation of the CaN/NFAT pathway may suppress TGF-β2 expression in dermal papilla cells, potentially contributing to CsA-associated hypertrichosis.

This study found that topical application of cyclosporin A and FK506 induces new hair growth in mice, while ascomycin and rapamycin do not, suggesting hair induction is not due to immunosuppression.

This study found that cyclosporine treatment led to clinical improvements in dogs with sebaceous adenitis, with noticeable benefits within four months and more substantial outcomes after 12 months of continuous therapy.

This review reports that ritlecitinib, baricitinib, and deuruxolitinib, all JAK inhibitors, are effective treatments for moderate-to-severe alopecia areata, with differences in selectivity and onset of action, and suggests that emerging biologic therapies may enhance treatment by offering more targeted immune modulation.

This case report describes a 69-year-old man diagnosed with stage 3 acute kidney injury secondary to new IgG kappa light chain multiple myeloma, where treatment with bortezomib-based therapy showed potential for kidney function salvage.

JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.

This study found that Baricitinib significantly reduced hair loss and immune response in a mouse model of alopecia areata.

In this case study, researchers reported that a patient with plaque alopecia areata experienced complete and sustained hair regrowth after treatment with 5-Fluorouracil and Bleomycin via microinfusion of medicines, despite initial cutaneous atrophy caused by intralesional corticosteroid therapy.